Scarica l'app Stockscreener
9.76
1.35%
0.13
Dopo l'orario di chiusura:
9.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.63
Aprire:
$9.72
Volume 24 ore:
719.45K
Relative Volume:
0.88
Capitalizzazione di mercato:
$532.90M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-4.1181
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
+4.27%
1M Prestazione:
+29.10%
6M Prestazione:
-18.87%
1 anno Prestazione:
-30.43%
Intervallo 1D:
$9.56
$10.06
Intervallo di 1 settimana:
$8.7032
$10.44
Portata 52W:
$5.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.76 | 511.03M | 8.78M | -104.70M | -82.68M | -2.37 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World
Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - sharewise
HC Wainwright Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $35.00 - Defense World
Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Stoke Therapeutics Provides Business Updates - citybiz
Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus
Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Gaining Ground: Stoke Therapeutics Inc (STOK) Closes Lower at 8.87, Down -1.44 - DWinneX
Wells Fargo & Company MN Has $185,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Form DEF 14AOther definitive proxy statements - ADVFN
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Biogen lowers annual earnings outlook, surpasses Q1 estimates By Investing.com - Investing.com Canada
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Market Highlights: Stoke Therapeutics Inc (STOK) Ends on a High Note at 9.52 - DWinneX
Stoke Therapeutics Inc (STOK) deserves deeper analysis - uspostnews.com
Geode Capital Management LLC Purchases 6,264 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? - MSN
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - NewsBreak: Local News & Alerts
Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com
(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World
Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
May 01 '25 |
Sale |
10.00 |
3,841 |
38,410 |
56,788 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):